The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States
The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States
复制标题
DOI：
10.1093/cid/civ334
复制
发表时间：
2015-08-15
影响因子：
11.8
通讯作者：
Ribner, Bruce S.
中科院分区：
文献类型：
--
作者：
Kraft, Colleen S.;Hewlett, Angela L.;Ribner, Bruce S.
背景。当前西非埃博拉病毒病（EVD）爆发已导致多人被医疗后送至其他国家进行临床管理。方法。我们报告了两名从西非转运至美国接受埃博拉病毒病治疗的患者。两名患者均接受了积极的支持性护理措施以及研究性治疗药物 (TKM-100802) 和恢复期血浆。结果。虽然一名患者病情危重，伴有多器官衰竭，需要机械通气和肾脏替代治疗，但两名患者均已康复，迄今为止没有出现严重的长期后遗症。结论。目前尚不清楚实验药物和恢复期血浆对这些患者的康复有何作用。需要进行前瞻性临床试验来描述研究疗法在埃博拉病毒病患者护理中的作用。
Background. The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management.Methods. We report two patients who were transported from West Africa to the United States for treatment of EVD. Both patients received aggressive supportive care measures, as well as an investigational therapeutic (TKM-100802) and convalescent plasma.Results. While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date.Conclusions. It is unclear what role the experimental drug and convalescent plasma had in the recovery of these patients. Prospective clinical trials are needed to delineate the role of investigational therapies in the care of patients with EVD.